Connect Biopharma (CNTB) late Friday said it received a deficiency notice from the Nasdaq for its American depository shares trading below $1 minimum price threshold for more than 30 consecutive days.
Under Nasdaq rules, the company has 180 days after receiving the notification letter to resolve the deficiency. Connect said it plans to monitor the price of its ADSs and may consider potential remedies if it appears that it cannot return to compliance by the Sept. 22 deadline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.